TIDMMPH
Mereo BioPharma Group plc
30 November 2020
Mereo BioPharma Reminds Market of Key Dates for AIM
Delisting
London and Redwood City, Calif., November 30, 2020 - Mereo
BioPharma Group plc (NASDAQ: MREO, AIM: MPH) ("Mereo" or "the
Company"), a clinical stage biopharmaceutical company focused on
oncology and rare diseases, provides a reminder of the key
deadlines in relation to the conversion of Ordinary Shares into
ADSs, as part of the previously announced delisting from AIM.
As previously announced on November 11, 2020, the last day of
trading of the Company's Ordinary Shares on AIM will be Thursday
December 17, 2020 and the proposed AIM Delisting will be effective
from 7.00am London time on Friday December 18, 2020. The Company
will retain the listing of its ADSs on NASDAQ under ticker symbol
MREO. Following the AIM Delisting, shares will only be tradeable on
NASDAQ.
Further information about the process to convert Ordinary Shares
into ADSs was provided in the announcement and circular published
by the Company on November 11, 2020. The information, forms and
contacts at the Company's registrar, Link Group (in respect of
completion of the block transfer participation request form for
certificated holders), and the Company's ADS depositary, Citibank
(in respect of the conversion by CREST holders of Ordinary Shares
to ADSs), are included on Mereo's website at
www.mereobiopharma.com/AIM-Delisting
The deadlines for conversion of Ordinary Shares held in either
certificated form or in CREST are as follows:
Last date for receipt by Link 4 December 2020 at 11.00 a.m.
Group from certificated shareholders London time
of duly completed block transfer
participation request forms and
original share certificates
Last date for receipt by Citibank 9 December 2020 at 3.00 p.m.
from CREST holders of duly completed London time
issuance forms
------------------------------
Shareholders who elect to convert their Ordinary Shares into
ADSs prior to the AIM Delisting will not incur a UK stamp duty, or
stamp duty reserve tax ("SDRT"), charge. However, it is expected
that shareholders who elect to convert their Ordinary Shares into
ADSs following the AIM Delisting will incur a stamp duty, or SDRT,
charge, at a rate of 1.5 per cent. of the market value of the
Ordinary Shares being converted, to the UK taxation authority,
HMRC.
Capitalized terms used but not defined in this announcement are
the same as those included in the announcement made on November 11,
2020.
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the
development and commercialization of innovative therapeutics that
aim to improve outcomes for oncology and rare diseases. Mereo's
lead oncology product candidate, etigilimab (Anti-TIGIT), has
completed a Phase 1a dose escalation clinical trial in patients
with advanced solid tumors and has been evaluated in a Phase 1b
study in combination with nivolumab in select tumor types. The
company recently announced initiation of a Phase 1b/2 study of
etigilimab in combination with an anti-PD-1/PDL-1 in a range of
different tumor types. Mereo's rare disease product portfolio
consists of setrusumab, which has completed a Phase 2b dose-ranging
study in adults with osteogenesis imperfecta (OI), as well as
alvelestat, which is being investigated in a Phase 2
proof-of-concept clinical trial in patients with alpha-1
antitrypsin deficiency (AATD) and in a Phase 1b/2 clinical trial in
COVID-19 respiratory disease.
Forward-Looking Statements
This Announcement contains "forward-looking statements." All
statements other than statements of historical fact contained in
this Announcement are forward-looking statements within the meaning
of Section 27A of the United States Securities Act of 1933, as
amended and Section 21E of the United States Securities Exchange
Act of 1934, as amended. Forward-looking statements usually relate
to future events and anticipated revenues, earnings, cash flows or
other aspects of our operations or operating results.
Forward-looking statements are often identified by the words
"believe," "expect," "anticipate," "plan," "intend," "foresee,"
"should," "would," "could," "may," "estimate," "outlook" and
similar expressions, including the negative thereof. The absence of
these words, however, does not mean that the statements are not
forward-looking. These forward-looking statements are based on the
Company's current expectations, beliefs and assumptions concerning
future developments and business conditions and their potential
effect on the Company. While management believes that these
forward-looking statements are reasonable as and when made, there
can be no assurance that future developments affecting the Company
will be those that it anticipates.
All of the Company's forward-looking statements involve known
and unknown risks and uncertainties some of which are significant
or beyond its control and involve assumptions that could cause
actual results to differ materially from the Company's historical
experience and its present expectations or projections.
These forward-looking statements are subject to risks and
uncertainties, including, among other things, those described in
the Company's latest Annual Report on Form 20-F, Reports on Form
6-K and other documents filed from time to time by the Company with
the United States Securities and Exchange Commission. The Company
wishes to caution investors not to place undue reliance on any
forward-looking statements, which speak only as of the date hereof.
The Company undertakes no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except to the extent
required by law.
Mereo BioPharma Contacts:
Mereo +44 (0)333 023 7300
Denise Scots-Knight, Chief Executive Officer
N+1 Singer (Nominated Adviser and Broker
to Mereo) +44 (0)20 7496 3081
Phil Davies
Will Goode
Burns McClellan (US Investor Relations
Adviser to Mereo) +01 212 213 0006
Lisa Burns
Lee Roth
FTI Consulting (UK Public Relations Adviser
to Mereo) +44 (0)20 3727 1000
Simon Conway
Ciara Martin
Investors investors@mereobiopharma.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABUBDBDDDDGGC
(END) Dow Jones Newswires
November 30, 2020 02:00 ET (07:00 GMT)
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Nov 2024 to Dec 2024
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Dec 2023 to Dec 2024
